YCYanfen Cui

Yanfen Cui

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yanfen Cui has a total of 47 co-authors. Here are the top co-authors by number of shared publications:

  • Fei Zhang

    Public Laboratory, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China

    4 shared publications
  • Ruifang Niu

    Public Laboratory, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China

    4 shared publications
  • He Zhang

    Public Laboratory, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China

    3 shared publications
  • Hui Guo

    Public Laboratory, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China

    3 shared publications
  • Hui Liu

    Public Laboratory, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China

    3 shared publications
  • Jianfei Tian

    Tianjin Medical University

    3 shared publications

Latest Publications

  • Fructose drives colorectal cancer progression by regulating crosstalk between cancer-associated fibroblasts and tumour cells

    by Yanfen Cui, Hui Liu, Laoming Zhang, He Zhang, Zhaosong Wang, Jiefu Wang, Zhiyong Wang, Lanlan Song, Hui Guo, Liming Liu, et al.

    Background Fructose has been identified as a potential alternative energy source for cancer cells, facilitated by the fructose-specific transporter GLUT5. Elevated GLUT5 expression in cancer cells has been associated with increased tumour aggressiveness. However, the role of fructose in remodelling the tumour microenvironment, particularly in modulating cancer-associated fibroblast (CAF) behaviour, remains underexplored. Objective This study aimed to elucidate the regulatory effects and molecular mechanisms of fructose-mediated CAF reprogramming in colorectal cancer (CRC) progression. Design The effects of fructose and fructose-cultured tumour cells on biological function of CAFs were detected. Metabolomics and transcriptomic analyses were used to characterise the fructose-regulated crosstalk network of tumour cells and CAFs. Furthermore, the relationships between GLUT5 expression level in CAFs and clinicopathological features and prognosis of patients with CRC were analysed. Results We demonstrate that fructose plays a dual role in promoting CRC progression by influencing both tumour cells and CAFs. GLUT5 is expressed in both CRC cells and CAFs, with its expression correlating with more advanced tumour stages and poorer outcomes in patients. Fructose metabolism in CAFs enhances their proliferation, migration and activation, while fructose utilisation by CRC cells leads to the release of nucleotides and amino acids. These metabolites activate CAFs and upregulate the expression of the chemokine CXCL14. This, in turn, promotes tumour cell migration and metastasis. Conclusions These findings reveal a novel mechanism by which fructose fosters tumour progression through the modulation of tumour-stroma interactions, and highlight the therapeutic potential of targeting fructose metabolism in CRC to disrupt the tumour-stroma crosstalk that drives malignancy.


  • Open Access

    Data from Fructose-Induced mTORC1 Activation Promotes Pancreatic Cancer Progression through Inhibition of Autophagy

    by Yanfen Cui, Jianfei Tian, Zhaosong Wang, Hui Guo, He Zhang, Zhiyong Wang, Hui Liu, Weijie Song, Liming Liu, Ruinan Tian, et al.

    Excessive fructose intake is associated with the occurrence, progression, and poor prognosis of various tumors. A better understanding of the mechanisms underlying the functions of fructose in cancer could facilitate the development of better treatment and prevention strategies. In this study, we investigated the functional association between fructose utilization and pancreatic ductal adenocarcinoma (PDAC) progression. Fructose could be taken up and metabolized by PDAC cells and provided an adaptive survival mechanism for PDAC cells under glucose-deficient conditions. GLUT5-mediated fructose metabolism maintained the survival, proliferation, and invasion capacities of PDAC cells in vivo and in vitro. Fructose metabolism not only provided ATP and biomass to PDAC cells but also conferred metabolic plasticity to the cells, making them more adaptable to the tumor microenvironment. Mechanistically, fructose activated the AMP-activated protein kinase (AMPK)–mTORC1 signaling pathway to inhibit glucose deficiency-induced autophagic cell death. Moreover, the fructose-specific transporter GLUT5 was highly expressed in PDAC tissues and was an independent marker of disease progression in patients with PDAC. These findings provide mechanistic insights into the role of fructose in promoting PDAC progression and offer potential strategies for targeting metabolism to treat PDAC.Significance:Fructose activates AMPK–mTORC1 signaling to inhibit autophagy-mediated cell death in pancreatic cancer cells caused by glucose deficiency, facilitating metabolic adaptation to the tumor microenvironment and supporting tumor growth.

  • Open Access

    Data from Fructose-Induced mTORC1 Activation Promotes Pancreatic Cancer Progression through Inhibition of Autophagy

    by Yanfen Cui, Jianfei Tian, Zhaosong Wang, Hui Guo, He Zhang, Zhiyong Wang, Hui Liu, Weijie Song, Liming Liu, Ruinan Tian, et al.

    Excessive fructose intake is associated with the occurrence, progression, and poor prognosis of various tumors. A better understanding of the mechanisms underlying the functions of fructose in cancer could facilitate the development of better treatment and prevention strategies. In this study, we investigated the functional association between fructose utilization and pancreatic ductal adenocarcinoma (PDAC) progression. Fructose could be taken up and metabolized by PDAC cells and provided an adaptive survival mechanism for PDAC cells under glucose-deficient conditions. GLUT5-mediated fructose metabolism maintained the survival, proliferation, and invasion capacities of PDAC cells in vivo and in vitro. Fructose metabolism not only provided ATP and biomass to PDAC cells but also conferred metabolic plasticity to the cells, making them more adaptable to the tumor microenvironment. Mechanistically, fructose activated the AMP-activated protein kinase (AMPK)–mTORC1 signaling pathway to inhibit glucose deficiency-induced autophagic cell death. Moreover, the fructose-specific transporter GLUT5 was highly expressed in PDAC tissues and was an independent marker of disease progression in patients with PDAC. These findings provide mechanistic insights into the role of fructose in promoting PDAC progression and offer potential strategies for targeting metabolism to treat PDAC.Significance:Fructose activates AMPK–mTORC1 signaling to inhibit autophagy-mediated cell death in pancreatic cancer cells caused by glucose deficiency, facilitating metabolic adaptation to the tumor microenvironment and supporting tumor growth.

  • Open Access

    Fructose-Induced mTORC1 Activation Promotes Pancreatic Cancer Progression through Inhibition of Autophagy

    by Yanfen Cui, Jianfei Tian, Zhaosong Wang, Hui Guo, He Zhang, Zhiyong Wang, Hui Liu, Weijie Song, Liming Liu, Ruinan Tian, et al.

    Excessive fructose intake is associated with the occurrence, progression, and poor prognosis of various tumors. A better understanding of the mechanisms underlying the functions of fructose in cancer could facilitate the development of better treatment and prevention strategies. In this study, we investigated the functional association between fructose utilization and pancreatic ductal adenocarcinoma (PDAC) progression. Fructose could be taken up and metabolized by PDAC cells and provided an adaptive survival mechanism for PDAC cells under glucose-deficient conditions. GLUT5-mediated fructose metabolism maintained the survival, proliferation, and invasion capacities of PDAC cells in vivo and in vitro. Fructose metabolism not only provided ATP and biomass to PDAC cells but also conferred metabolic plasticity to the cells, making them more adaptable to the tumor microenvironment. Mechanistically, fructose activated the AMP-activated protein kinase (AMPK)–mTORC1 signaling pathway to inhibit glucose deficiency-induced autophagic cell death. Moreover, the fructose-specific transporter GLUT5 was highly expressed in PDAC tissues and was an independent marker of disease progression in patients with PDAC. These findings provide mechanistic insights into the role of fructose in promoting PDAC progression and offer potential strategies for targeting metabolism to treat PDAC. Significance: Fructose activates AMPK–mTORC1 signaling to inhibit autophagy-mediated cell death in pancreatic cancer cells caused by glucose deficiency, facilitating metabolic adaptation to the tumor microenvironment and supporting tumor growth.


  • Open Access

    Survival-associated Metabolic Genes in Colon and Rectal Cancers

    by Yanfen Cui, Baoai Han, He Zhang, Zhiyong Wang, Hui Liu, Fei Zhang, Ruifang Niu

    Background Uncontrolled proliferation is the most prominent biological feature of tumors. To rapidly proliferate and maximize the use of available nutrients, tumor cells regulate their metabolic behavior and the expression of metabolism-related genes (MRGs). In this study, we aimed to construct prognosis models for colon and rectal cancers, using MRGs to indicate the prognoses of patients. MethodsWe first acquired the gene expression profiles of colon and rectal cancers from the TCGA and GEO database, and utilized univariate Cox analysis, lasso regression, and multivariable cox analysis to identify MRGs for risk models. Then GSEA and KEGG functional enrichment analysis were utilized to identify the metabolism pathway of MRGs in the risk models and analyzed these genes comprehensively using GSCALite.ResultsEight genes (CPT1C, PLCB2, PLA2G2D, GAMT, ENPP2, PIP4K2B, GPX3, and GSR) in the colon cancer risk model and six genes (TDO2, PKLR, GAMT, EARS2, ACO1, and WAS) in the rectal cancer risk model were identified successfully. Multivariate Cox analysis indicated that the models predicted overall survival accurately and independently for patients with colon or rectal cancer. Furthermore, we identified the metabolism pathway of MRGs in the risk models and analyzed these genes comprehensively. Then, we verified the prognosis model in independent colon cancer cohorts (GSE17538) and detected the correlations of the protein expression levels of GSR and ENPP2 with prognosis for colon or rectal cancer. ConclusionsOur findings demonstrated that 14 MRGs are potential prognostic biomarkers and therapeutic targets of colorectal cancer.

  • Open Access

    Acute Endoplasmic Reticulum Stress-Independent Unconventional Splicing of XBP1 mRNA in the Nucleus of Mammalian Cells

    by Yuanyuan Wang, Pan Xing, Wenjing Cui, Wenwen Wang, Yanfen Cui, Guoguang Ying, Xin Wang, Binghui Li

    The regulation of expression of X-box-binding protein-1 (XBP1), a transcriptional factor, involves an unconventional mRNA splicing that removes the 26 nucleotides intron. In contrast to the conventional splicing that exclusively takes place in the nucleus, determining the location of unconventional splicing still remains controversial. This study was designed to examine whether the unconventional spicing of XBP1 mRNA could occur in the nucleus and its possible biological relevance. We use RT-PCR reverse transcription system and the expand high fidelity PCR system to detect spliced XBP1 mRNA, and fraction cells to determine the location of the unconventional splicing of XBP1 mRNA. We employ reporter constructs to show the presence of unconventional splicing machinery in mammal cells independently of acute endoplasmic reticulum (ER) stress. Our results reveal the presence of basal unconventional splicing of XBP1 mRNA in the nucleus that also requires inositol-requiring transmembrane kinase and endonuclease 1α (IRE1α) and can occur independently of acute ER stress. Furthermore, we confirm that acute ER stress induces the splicing of XBP1 mRNA predominantly occurring in the cytoplasm, but it also promotes the splicing in the nucleus. The deletion of 5′-nucleotides in XBP1 mRNA significantly increases its basal unconventional splicing, suggesting that the secondary structure of XBP1 mRNA may determine the location of unconventional splicing. These results suggest that the unconventional splicing of XBP1 mRNA can take place in the nucleus and/or cytoplasm, which possibly depends on the elaborate regulation. The acute ER stress-independent unconventional splicing in the nucleus is most likely required for the maintaining of day-to-day folding protein homeostasis.


  • Open Access

    High Levels of KAP1 Expression Are Associated with Aggressive Clinical Features in Ovarian Cancer

    by Yanfen Cui, Shaobin Yang, Xin Fu, Jingwen Feng, Shilei Xu, Guoguang Ying

    KAP1 is an universal corepressor for Kruppel-associated box zinc finger proteins in both normal and tumor cells. In this study, the biological function and clinical significance of KAP1 expression in ovarian cancer were investigated. Immunohistological staining of KAP1 was evaluated in 111 patients with ovarian epithelial cancer, 15 with ovarian borderline tumor, and 20 normal ovarian tissue. The correlations of KAP1 expression with clinicopathological features were studied. Kaplan-Meier analysis and Cox proportional hazard modeling were used to assess overall survival to analyze the effect of KAP1 expression on the prognosis of ovarian cancer. The positive rates of KAP1 were significantly higher in ovarian epithelial cancer (55.7%) and borderline tumor (20.0%) than in normal ovarian tissue (5.0%) (all p < 0.01). KAP1 expression correlated significantly with clinical stage (χ2 = 14.57, p < 0.0001), pathological grade (χ2 = 6.06, p = 0.048) and metastases (χ2 =10.38, p = 0.001). Patients with high KAP 1 levels showed poor survival (p < 0.0001). Multivariate analysis showed that KAP1 high expression was an independent predictor for ovarian cancer patients (hazard ratio = 0.463; 95% confidence interval = 0.230–0.9318, p = 0.031). Functionally, depletion of KAP1 by siRNA inhibited ovarian cancer cell proliferation, cell migration. KAP1 expression correlated with aggressive clinical features in ovarian cancer. High KAP1 expression was a prognostic factor of ovarian cancer.


  • Secreted CLU is associated with the initiation of triple-negative breast cancer

    by Danfang Zhang, Baocun Sun, Xiulan Zhao, Yanfen Cui, Shaoyan Xu, Xueyi Dong, Jianmin Zhao, Jie Meng, Xiaohua Jia, Jiadong Chi

    Triple-negative breast cancer, which is negative for the estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2, represents about 15-26% of all breast cancer cases. However, because of its genotype, a triple-negative disease accounts for a remarkable metastasis and mortality. Moreover, no targeted treatment is available because the molecular mechanism of triple-negative breast cancer initiation is still unclear. Secreted clusterin (sCLU) is associated with the refractory to anti-estrogen in breast cancer cells. We investigated the sCLU expression in 384 human breast cancer cases, including 61 triple-negative cases, as well as the relationship between sCLU and clinical pathological characteristics. Triple-negative patients (75.4%) were positive for sCLU based on immunohistochemical analysis, and sCLU expression in this subtype was proven related to a larger tumor size, an axillary node status, and a higher clinical stage. Furthermore, we used a spontaneous breast cancer mouse strain with a triple-negative genotype to detect the sCLU dynamic expression in breast cancer oncogenesis using western blot and real-time polymerase chain reaction. The sCLU mRNA and protein expression in the tumor and hyperplastic epithelium were upregulated and reached a peak compared with those of a normal mammary gland. These results suggest that sCLU is involved in the initiation of triple-negative breast cancer, which is beneficial for the clinical trial design of an anti-CLU treatment for triple-negative breast cancer.